In February 2021, we conducted a global survey of professionals working in oligonucleotide, peptide, mRNA and genome editing to find out how organizations in the industry are now working and what key strategies may have changed as a result of the COVID-19 pandemic.
Quality control and control of impurities has remained the biggest challenge for the respondents developing peptide therapeutics since our last report in 2019.
Delivery systems were the top mentioned by those working on oligonucleotides, a shift away from safety which was the top mention in 2019.
